Continuing in the vein of IHL-675A ....the anti-inflammatory go to for inflammation related diseases
Myocarditis, and Acute Myocarditis is characterised by decreased heart function due to an inflammatory response triggered in most cases by viral infections. Inflammation of the heart muscle under these conditions will usually recede with a clearing of the associated viral infection, in approx. 10 days. COPD is of course another participator in causing / aggravating and perpetuating this debilitating condition - hence the link to my previous COPD post. The inflammatory heart condition persists in a percentage of those affected in concert with what is believed to be a contributory auto immune response....( also present in the COPD response) The flow on effects are further characterised by signs / symptoms potentially leading to heart failure. Patient treatments for this escalating condition are based in the 'standard of care' for patients with impaired heart function leading to heart failure......the condition and associated damage is progressed as the underlying inflammation remains untreated.
Remembering, as with COPD, there is no specific treatment for myocarditis and acute myocarditis, potentially IHL 675A could well prove to be an emerging designated treatment for exactly this condition.
IHL-675A 'the treatment' potentially for inflammatory related diseases. The 'standard of care' may well be rewritten by Incannex and this anti-inflammatory drug treatment. Again, the addressable market here is staggering
